fasedienol
Small molecule
Evidence outlook · lead readout
Palisade-1 (NCT04754802) · Social Anxiety Disorder
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
Palisade-1 (NCT04754802): The trial was randomized, triple-blind, placebo-controlled, and included 224 participants, with a clinical symptom measure (SUDS) as the primary endpoint. The primary comparison was not statistically significant: mean SUDS at Visit 3 was 62.3 with fasedienol versus 61.3 with placebo (p=0.5063; 95% CI for the difference, -3.2 to 6.4), so the findings provide well-designed but unclear evidence of benefit.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Palisade-1 NCT04754802 · Social Anxiety Disorder The trial was randomized, triple-blind, placebo-controlled, and included 224 participants, with a clinical symptom measure (SUDS) as the primary endpoint. The primary comparison was not statistically significant: mean SUDS at Visit 3 was 62.3 with fasedienol versus 61.3 with placebo (p=0.5063; 95% CI for the difference, -3.2 to 6.4), so the findings provide well-designed but unclear evidence of benefit. Registry: NCT04754802 | 3 | Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)) 2022-06-22 | Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)): PH94B — Visit 2: 77.7 score on a scale (Standard Deviation 11.67); Visit 3: 62.3 score on a scale (Standard Deviation 19.4) | Placebo — Visit 2: 78.2 score on a scale (Standard Deviation 12.42); Visit 3: 61.3 score on a scale (Standard Deviation 19.56) | Partial signal | link ↗ |
View 2 more trials
PALISADE-3 NCT06358651 · Social Anxiety Disorder PALISADE-3 is a randomized, triple-masked, placebo-controlled Phase 3 trial in social anxiety disorder with the SUDS score as its primary endpoint. The sponsor reports that it did not achieve its primary or secondary endpoints. Result from the sponsor's SEC filing; the registry has no posted results. Registry: NCT06358651 | 3 | Subjective Units of Distress Scale (SUDS) (7 days (Visit 2 to Visit 3)) 2025-10-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
PALISADE-4 NCT06615557 · Social Anxiety Disorder PALISADE-4 is a randomized, triple-masked, placebo-controlled Phase 3 trial in social anxiety disorder (n=238) with the SUDS score as its primary endpoint. The sponsor reports that it did not achieve its primary endpoint in the overall population; a post-hoc subgroup result is not the primary analysis. Result from the sponsor's SEC filing; the registry has no posted results. Registry: NCT06615557 | 3 | Subjective Units of Distress Scale (SUDS) (7 days (Visit 2 to Visit 3)) 2026-04-21 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Social Anxiety Disorder: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fasedienol: this drug | Phase 3 | Small molecule | Nasal chemosensory receptors | Partial signal | NCT04754802: Subjective Units of Distress Scale (SUDS) Score (Visit 2 (Baseline; Day 0) to Visit 3 (Day 7 ± 2 days)): PH94B — Visit 2: 77.7 score on a scale (Standard Deviation 11.67); Visit 3: 62.3 score on a scale (Standard Deviation 19.4) | Placebo — Visit 2: 78.2 score on a scale (Standard Deviation 12.42); Visit 3: 61.3 score on a scale (Standard Deviation 19.56) missed | |
| EMP-01 | Phase 2 | Small molecule | Serotonergic system (MDMA-class entactogen) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent